NTS071 to Target p53 Y220C Mutation in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 18/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! As you probably know, last week was the week of AACR 2025 (American Association for Cancer Research) and AUA 2025 (American Urological Association), so we have a very packed newsletter! Enjoy the read! Stay strong and fight on! As […]
Transdermal Estradiol: A Cost-Saving, Quality-of-Life Boost for Prostate Cancer Therapy
/0 Comments/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology oncolytic virus p53 mutation personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics